Yahoo
NasdaqCM - Nasdaq Real Time Price USD

RenovoRx, Inc. (RNXT)

1.1300 -0.0600 (-5.04%)
At close: November 6 at 4:00:00 PM EST
1.1700 +0.0400 (+3.54%)
After hours: November 6 at 5:03:52 PM EST
Chart Range Bar
Loading chart for RNXT
Chart does not reflect overnight price.
  • Previous Close 1.1900
  • Open 1.0500
  • Bid 1.1500 x 200
  • Ask 1.2400 x 100
  • Day's Range 0.8800 - 1.2050
  • 52 Week Range 0.7010 - 2.5900
  • Volume 1,845,285
  • Avg. Volume 821,795
  • Market Cap (intraday) 54.523M
  • Beta (5Y Monthly) 1.17
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3100
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 7.25
  • Zacks Rating Neutral

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

renovorx.com

17

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RNXT
34.52%
S&P 500 (^GSPC)
7.76%

1-Year Return

RNXT
16.98%
S&P 500 (^GSPC)
9.77%

3-Year Return

RNXT
4.24%
S&P 500 (^GSPC)
68.96%

5-Year Return

RNXT
78.52%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.07M
Earnings -3.65M
Profit Margin -342.12%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-3M
-2M
-1M
0
1M
-1200.0%
-1000.0%
-800.0%
-600.0%
-400.0%

Analyst Insights

View More

Analyst Price Targets

3.00
7.25 Average
1.1300 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/28/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 14 -> 14.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -64.90%

  • Return on Equity (ttm)

    -125.23%

  • Revenue (ttm)

    1.98M

  • Net Income Avi to Common (ttm)

    -12.29M

  • Diluted EPS (ttm)

    -0.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.48M

  • Total Debt/Equity (mrq)

    4.34%

  • Levered Free Cash Flow (ttm)

    -6.65M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: